PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study

Summary

Research Purpose

The objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA).

Study Content

This clinical trial is a randomized (1:1), multicenter, parallel-group, controlled study. AGA patients aged 18 to 60 years presenting to the participating centers will be recruited. After providing informed consent, eligible patients who meet the inclusion/exclusion criteria will be randomized in a 1:1 ratio, with separate randomization schedules for male and female patients, into either the experimental group (PRP combined with BTX-A injection) or the control group (PRP injection only). A total of 76 patients will be enrolled.

Control Group: Subjects randomized to the control group will receive PRP injection therapy. The PRP will be administered intradermally (at a depth of approximately 1.5-2.5 mm, with injection points 1 cm apart) into the scalp area (defined as ≥12 cm from the lateral canthus and ≥9 cm from the top of the ear, encompassing the frontal, temporal, parietal, and occipital regions) at a dose of 0.1 ml/cm². The treatment regimen consists of monthly injections, 4 ml per session, for a total of 3 consecutive sessions.

Experimental Group: Subjects randomized to the experimental group will receive injections using the same method and frequency as the control group. For the first session, the injection will consist of 100U of BTX-A reconstituted in 4 ml of PRP. The second and third sessions will be identical to those in the control group (PRP injection only).

Follow-up Assessments: For all subjects, a safety evaluation will be conducted 14 days after the first treatment, along with scalp care guidance provided by the investigator. Subsequent safety and efficacy assessments will be performed at 1, 2, 3, and 6 months following the initial treatment.

Conditions

• Androgenetic Alopecia (AGA)

Interventions

COMBINATION_PRODUCT

Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s)

Treatment Protocol: Subjects in the PRP combined with Botulinum Toxin Type A (BTX-A) treatment group received injections using the same method and frequency as the PRP control group. For the first session, the injection consisted of 100 units of BTX-A reconstituted in 4 ml of PRP. The second and third sessions were identical to those administered to the control group (PRP injection only). Follow-up Assessments: A safety evaluation was conducted for each subject 14 days after the initial treatment, during which the investigator provided scalp care guidance. Subsequent evaluations for both safety and efficacy were performed at 1, 2, 3, and 6 months following the initial treatment.

OTHER

PRP-only injection into the alopecic area

Treatment Protocol for the PRP-Only Control Group: Subjects in the PRP-only control group will receive PRP injection therapy alone. The PRP will be administered intradermally at a depth of approximately 1.5-2.5 mm, with injection points spaced 1 cm apart, into the predefined scalp area (≥12 cm from the lateral canthus and ≥9 cm from the top of the ear, encompassing the frontal, temporal, parietal, and occipital regions). The injections will be administered at a dose of 0.1 ml/cm². The treatment regimen consists of monthly sessions, with 4 ml of PRP injected per session, for a total of 3 consecutive sessions. Follow-up Assessments: A safety evaluation will be conducted for each subject 14 days after the initial treatment, during which the investigator will provide personalized scalp care guidance. Subsequent comprehensive assessments evaluating both safety and efficacy will be performed at 1, 2, 3, and 6 months following the initial treatment.

Sponsors & Collaborators

• Nanfang Hospital, Southern Medical University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-09

Primary Completion

2026-08-31

Completion

2026-08-31

Countries

• China

Study Locations